Natural Versus Synthetic Inhibition of the PI3K Pathway Causing Over-Expression and Reduced Apoptosis to HER 2 Leading to ER + / HER2 + Breast Cancer

Amlan Chakraborty, Apoorv Gupta, Pranav Patni

Research output: Contribution to journalArticlepeer-review

Abstract

Amplification or over-expression of the HER2 gene occurs in approximately 30% of breast cancers. HER2 proteins have been shown to form clusters in cell membranes that may play a role in tumorigenesis. It has been found that patients with ER+ (Estrogen receptor positive)/HER2+ compared with ER-/HER2+ breast cancers may actually benefit more from drugs that inhibit the PI3K/AKT molecular pathway. The PI3K/AKT/mTOR pathway is an intracellular signalling pathway important in apoptosis and hence cancer. In case of ER+/HER2+ breast cancer this pathway is overactive, thus reducing apoptosis and allowing proliferation. Various natural compounds, including epigallocatechin gallate (EGCG), caffeine, curcumin, resveratrol and Taxol, have been found to inhibit PI3K pathway. Also, synthetic inhibitors like Wortmanin and LY294002 has been found in inhibiting the PI3K pathway.
Original languageEnglish
JournalJournal of Applied Bioinformatics and computational Biology
Volume3
Issue number1
Publication statusPublished - 2014

Fingerprint

Dive into the research topics of 'Natural Versus Synthetic Inhibition of the PI3K Pathway Causing Over-Expression and Reduced Apoptosis to HER 2 Leading to ER + / HER2 + Breast Cancer'. Together they form a unique fingerprint.

Cite this